UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): April 15, 2013

 

ONCOSEC MEDICAL INCORPORATED

(Exact name of registrant as specified in its charter)

 

Nevada

 

000-54318

 

98-0573252

(State or other jurisdiction
of incorporation)

 

(Commission
File Number)

 

(I.R.S. Employer
Identification No.)

 

4690 Executive Drive, Suite 250
San Diego, California, 92121

(Address of principal executive offices)

 

Registrant’s telephone number, including area code: (855) 662-6732

 

Not Applicable

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

o    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 



 

Item 5.07 Submission of Matters to a Vote of Security Holders.

 

On April 15, 2013, OncoSec Medical Incorporated (the “Company”) held its 2013 Annual Meeting of Stockholders (the “Annual Meeting”) at the Company’s principal executive offices located at 4690 Executive Drive, Suite 250, San Diego, CA 92121.

 

The final voting results on the matters presented at the Annual Meeting were as follows:

 

Proposal 1 — to elect four directors to our Board of Directors to serve for a term of one year or until their successors are duly elected and qualified

 

Directors

 

For

 

Withheld

 

Broker Non-Votes

 

Dr. Avtar Dhillon

 

34,828,149

 

4,054,692

 

48,228,456

 

Dr. Anthony Maida

 

34,919,289

 

3,963,552

 

48,228,456

 

Dr. James DeMesa

 

34,913,289

 

3,969,552

 

48,228,456

 

Punit Dhillon

 

34,752,759

 

4,130,082

 

48,228,456

 

 

Proposal 2 — to ratify the appointment of Mayer Hoffman McCann P.C. as the Company’s independent registered public accounting firm for the fiscal year ending July 31, 2013

 

For

 

Against

 

Abstain

 

Broker Non-
Vote

 

85,059,738

 

1,116,935

 

934,624

 

 

 

Proposal 3 — to approve an amendment to the Company’s 2011 Stock Incentive Plan (the “Plan”) to authorize the issuance of an additional 3,800,000 shares of common stock under the Plan

 

For

 

Against

 

Abstain

 

Broker Non-
Vote

 

35,421,962

 

3,189,397

 

271,482

 

48,228,456

 

 

Proposal 4 — to approve, on an advisory basis, the compensation of the Company’s named executive officers

 

For

 

Against

 

Abstain

 

Broker Non-
Vote

 

36,117,012

 

2,444,045

 

321,784

 

48,228,456

 

 

Proposal 5 — to approve, on an advisory basis, a three year frequency of holding a stockholder advisory vote on the compensation of the Company’s executive officers

 

1 Year

 

2 Years

 

3 Years

 

Abstain

 

2,676,414

 

1,059,768

 

34,844,315

 

302,344

 

 

In consideration of the results of the stockholder vote on Proposal 5 set forth above, the Board of Directors of the Company has determined to hold a stockholder advisory vote on the compensation of the Company’s executive officers once every three years.

 

1



 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

ONCOSEC MEDICAL INCORPORATED

 

 

Dated: April 18, 2013

By:

/s/ Punit Dhillon

 

 

Name: Punit Dhillon

 

 

Title: President & Chief Executive Officer

 

2